Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for its best-selling ...
May 18, 2026 10:44 AM EDT R&D Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule Max Gelman Senior Editor An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that